Laboratory Corp of America HoldingsFind Ratings Reports
LABORATORY CP OF AMER HLDGS's gross profit margin for the fourth quarter of its fiscal year 2016 is essentially unchanged when compared to the same period a year ago. The company has grown its sales and net income during the past quarter when compared with the same quarter a year ago, and although its growth in net income has outpaced the industry average, its revenue growth has not. LABORATORY CP OF AMER HLDGS has average liquidity. Currently, the Quick Ratio is 1.12 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
During the same period, stockholders' equity ("net worth") has increased by 11.35% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY16||Q4 FY15|
|Net Sales ($mil)||2428.4||2300.5|
|Net Income ($mil)||184.4||110.0|
|Balance Sheet||Q4 FY16||Q4 FY15|
|Cash & Equiv. ($mil)||433.6||716.4|
|Total Assets ($mil)||14247.0||14221.7|
|Total Debt ($mil)||5849.5||6417.0|
|Profitability||Q4 FY16||Q4 FY15|
|Gross Profit Margin||35.81||35.45|
|Return on Assets||5.13||3.07|
|Return on Equity||13.29||8.85|
|Debt||Q4 FY16||Q4 FY15|
|Share Data||Q4 FY16||Q4 FY15|
|Shares outstanding (mil)||102.7||101.3|
|Div / share||0.0||0.0|
|Book value / share||53.61||48.81|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||795064.0||740151.0|
BUY. This stock's P/E ratio indicates a discount compared to an average of 28.96 for the Health Care Providers & Services industry and a discount compared to the S&P 500 average of 26.73. To use another comparison, its price-to-book ratio of 2.69 indicates valuation on par with the S&P 500 average of 2.98 and a discount versus the industry average of 3.42. The price-to-sales ratio is well below the S&P 500 average, but well above the industry average. Upon assessment of these and other key valuation criteria, LABORATORY CP OF AMER HLDGS proves to trade at a discount to investment alternatives within the industry.
|LH 20.60||Peers 28.96||LH 12.59||Peers 12.72|
Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.
LH is trading at a significant discount to its peers.
Average. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
LH is trading at a valuation on par to its peers.
|LH 13.92||Peers 16.02||LH 0.56||Peers 1.25|
Average. An average price-to-projected earnings ratio can signify an industry neutral stock price and average future growth expectations.
LH is trading at a valuation on par with its peers.
Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
LH trades at a significant discount to its peers.
|LH 2.69||Peers 3.42||LH 63.93||Peers 19.88|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
LH is trading at a discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
LH is expected to have an earnings growth rate that significantly exceeds its peers.
|LH 1.54||Peers 0.87||LH 11.07||Peers 11.77|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
LH is trading at a significant premium to its industry.
Average. Comparing a company's sales growth to its industry helps to determine if the company is adding or losing market share.
LH is keeping pace with its peers on the basis of sales growth.